4D pharma (Longevity Acquisition) ^{Priced, Nasdaq: LBPS.XX}

Our efforts in identifying prospective target businesses will not be limited to a particular country, although we intend to focus on businesses that have their primary operations located in China. We believe that we will add value to these businesses primarily by providing them with access to the U.S. capital markets. We will seek to capitalize on the strength of our management team. Our team consists of experienced financial services and accounting professionals and senior operating executives of companies in China. Collectively, our officers and directors have decades of experience in mergers and acquisitions, and operating companies in China. We believe we will benefit from their accomplishments, and specifically their current activities in China market, in identifying attractive acquisition opportunities. Our officers and director nominees have no prior experience consummating a business combination for a blank check company. We will seek to identify targets that are likely to provide attractive financial returns through business combinations. We have yet to determine a time frame, an investment amount or any other criteria, which would trigger our search for business opportunities outside of China.